EGFR and non-small cell lung carcinoma: Benmelstobart (also known as TQ-B2450), a novel humanized anti-programmed cell death ligand 1 (PD-L1) antibody, has shown preliminary efficacy in patients with advanced solid tumors, including NSCLC (ORR, 32.8%; disease control rate [DCR], 81.8%).12 Anlotinib, an oral multi-target TKI, has been approved for the treatment of NSCLC in China.6,13,14 In the phase I/II ALTER-L038 study, the efficacy and safety of the chemotherapy-free combination therapy comprising benmelstobart and anlotinib were evaluated in patients with EGFR-positive advanced NSCLC following resistance to EGFR-TKIs.